Présentation de l'entreprise
OSR Holdings, Inc. operates as a healthcare holding company dedicated to developing a strategic portfolio of therapies and healthcare solutions across the United States, Switzerland, and South Korea. The firm focuses specifically on immunotherapy products, including VXM01, which is an immuno-oncology candidate currently undergoing phase 2 clinical trials for the treatment of glioblastoma. This entity functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, where success is often measured by clinical trial outcomes and regulatory approvals rather than immediate profitability. The company's scale is defined by a market capitalization of $16.30M and a trailing twelve-month revenue of $2.91M, while the specific employee count is not disclosed in available filings. These valuation and revenue figures indicate that OSR Holdings, Inc. is a micro-cap biotechnology firm operating in a high-risk, high-reward segment of the market, where capital allocation toward research and development is prioritized over short-term earnings generation, resulting in a small market presence relative to large-cap pharmaceutical peers.
Santé financière
The company reported a revenue of $2.91M for the trailing twelve-month period, yet this generated a net income of $-18,010,900, revealing a significant gap between top-line sales and bottom-line earnings that points to substantial operating expenses or research costs not covered by current revenue streams. This loss is further contextualized by an EBITDA of $-9,029,896, which suggests that core operational activities, excluding non-cash items and financing costs, are currently generating a negative cash conversion. Despite the net income loss, the company maintains a free cash flow of $9.38M, which provides a degree of financial flexibility by indicating that operational cash generation exceeds capital expenditure requirements, potentially allowing for continued R&D investment or debt servicing. However, the liquidity picture is constrained by a current ratio of 0.16, which indicates that the company's current assets are significantly lower than its current liabilities, suggesting potential challenges in meeting short-term obligations without refinancing or asset sales. The balance sheet shows a cash position of $1.70M against total debt of $4.40M, resulting in a debt-to-equity ratio of 3.47, which characterizes the company as highly leveraged with a conservative liquidity posture that carries elevated financial risk. Profitability metrics reflect this structural challenge, with a gross margin of 19.1%, an operating margin of -1674.8%, and a profit margin of 0.0%, illustrating that while product costs are controlled relative to revenue, overall operational inefficiencies or heavy losses have driven the bottom line deeply into negative territory. Furthermore, the return on equity stands at -20.0% and the return on assets is -6.6%, metrics that reveal management has not yet achieved positive returns on the capital invested or the assets held, a common characteristic for early-stage biotechnology firms but one that signals a prolonged path to profitability.
Évaluation de la valorisation
Valuation multiples for the company are constrained by its lack of earnings, as the trailing P/E ratio is N/A and the forward P/E ratio is also N/A, implying that traditional earnings-based valuation methods are not applicable and that investors are pricing the stock based on asset value or potential future clinical milestones. In the absence of earnings multiples, the price-to-book ratio stands at 0.14, indicating that the market values the company at 14% of its book value, which suggests a deep discount to the net asset value or significant market skepticism regarding the recoverability of those assets. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 5.61 and an EV/EBITDA of -7.58, suggesting that the market is willing to pay a premium relative to sales despite the negative enterprise value multiple driven by the net debt position. Price action over the last year has been volatile, with a 52-week high of $1.79 and a 52-week low of $0.38, meaning the stock is currently trading within this compressed range but significantly below the yearly peak. The stock exhibits a beta of 0.59, which indicates that its price volatility is less than half that of the broader market, suggesting it may be less sensitive to general market fluctuations but remains highly idiosyncratic in its risk profile.
Growth & Income
The growth profile of the company is characterized by a revenue growth of -58.3% year-over-year, while the earnings growth rate is N/A due to the company's current loss status. The contraction in revenue implies a reduction in sales volume or a cessation of specific revenue-generating activities, which is typical for clinical-stage biotechnology companies shifting focus to later-stage development, but it does not imply earnings are growing faster than revenue since the earnings base is negative. As the company does not distribute dividends, the dividend yield is N/A and the payout ratio is 0.0%, which confirms that the firm retains all generated cash and any losses to fund ongoing operations and clinical trials rather than returning capital to shareholders. Consequently, the overall growth and income profile is defined by negative revenue momentum and zero dividend distribution, reflecting a capital-intensive growth strategy where value creation is contingent upon future clinical success and regulatory approval rather than current cash returns or income generation.